Galapagos' Strategic Shift: Betting On CAR-T And A Fresh Start (Rating Upgrade)
Galapagos shifts to CAR-T therapy with GLPG5101, targeting pivotal trials by 2026. Click here to find out why I rate GLPG ...
pharmaphorum4d
Galapagos unveils plan to split, hiving off its drugs unit
Meanwhile, the Galapagos cell therapy business will start its new life with around €500 million in cash to bring forward programmes led by CD19-targeting CAR-T candidate, GLPG5101, for relapsed ...
Disount To Net Cash For A Promising CAR-T Company
Galapagos NV’s split could unlock value despite short-term share decline. Learn why GLPG stock’s strategic focus offers ...
Galapagos price target lowered to EUR 22 from EUR 28 at Deutsche Bank
Deutsche Bank lowered the firm’s price target on Galapagos (GLPG) to EUR 22 from EUR 28 and keeps a Hold rating on the shares.Discover the Best ...
Galapagos (GLPG) Gets a Hold from RBC Capital
In a report released on February 13, Brian Abrahams from RBC Capital maintained a Hold rating on Galapagos (GLPG – Research Report), with a ...
Galapagos NV: Galapagos receives transparency notification and 13D filing from Tang Capital
CET; regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification and 13D filing from Tang Capital. Pursuant to Belgian ...